Alector, Inc. (ALEC)
1.975
+0.14
(+7.34%)
USD |
NASDAQ |
Oct 19, 15:49
Alector Enterprise Value : 65.41M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 65.41M |
| October 15, 2026 | 73.22M |
| October 14, 2026 | 69.87M |
| October 13, 2026 | 68.76M |
| October 12, 2026 | 92.21M |
| October 09, 2026 | 92.21M |
| October 08, 2026 | 85.51M |
| October 07, 2026 | 74.34M |
| October 06, 2026 | 62.06M |
| October 05, 2026 | 82.16M |
| October 02, 2026 | 62.06M |
| October 01, 2026 | 67.64M |
| September 30, 2026 | 66.53M |
| September 29, 2026 | 68.76M |
| September 28, 2026 | 74.34M |
| September 25, 2026 | 77.69M |
| September 24, 2026 | 74.34M |
| September 23, 2026 | 85.51M |
| September 22, 2026 | 84.39M |
| September 21, 2026 | 75.46M |
| September 18, 2026 | 73.22M |
| September 17, 2026 | 66.53M |
| September 16, 2026 | 74.90M |
| September 15, 2026 | 87.18M |
| September 14, 2026 | 106.72M |
| Date | Value |
|---|---|
| September 11, 2026 | 98.91M |
| September 10, 2026 | 98.91M |
| September 09, 2026 | 113.42M |
| September 08, 2026 | 135.75M |
| September 04, 2026 | 134.64M |
| September 03, 2026 | 140.22M |
| September 02, 2026 | 163.67M |
| September 01, 2026 | 127.94M |
| August 31, 2026 | 112.30M |
| August 28, 2026 | 121.24M |
| August 27, 2026 | 126.82M |
| August 26, 2026 | 134.64M |
| August 25, 2026 | 123.47M |
| August 24, 2026 | 116.77M |
| August 21, 2026 | 123.47M |
| August 20, 2026 | 112.30M |
| August 19, 2026 | 131.29M |
| August 18, 2026 | 106.72M |
| August 17, 2026 | 88.86M |
| August 14, 2026 | 78.81M |
| August 13, 2026 | 87.74M |
| August 12, 2026 | 100.02M |
| August 11, 2026 | 93.32M |
| August 10, 2026 | 48.66M |
| August 07, 2026 | 58.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.664B |
| Oncolytics Biotech, Inc. | 58.41M |
| Sangamo Therapeutics, Inc. | 37.40M |
| Sarepta Therapeutics, Inc. | 2.064B |
| Anixa Biosciences, Inc. | 77.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.99M |
| Revenue (Quarterly) | 3.32M |
| Total Expenses (Quarterly) | 26.31M |
| EPS Diluted (Quarterly) | -0.2067 |
| Gross Profit Margin (Quarterly) | 38.28% |
| Profit Margin (Quarterly) | -692.5% |
| Earnings Yield | -55.30% |
| Normalized Earnings Yield | -52.81 |